Drugs / Lepirudin

Regulatory milestones approvals, filings & regulatory actions · 2 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Withdrawn EU (EMA) Refludan 2012-04-24 europa.eu
Approved EU (EMA) Refludan 1997-03-13 europa.eu

Trials 2 · a red edge is where a trial was stopped

1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT00003726 Nov 1998 → Jul 2001 lung cancer Dartmouth-Hitchcock Medical Center Terminated No outcome recorded
Phase 21 trial
Phase 2 NCT00039767 May 2002 → Apr 2006 thrombotic disease National Institutes of Health Clinical Center (CC) Completed No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT00798525 Comparator Jan 2009 → Mar 2012 heparin-induced thrombocytopenia Heinrich-Heine University, Duesseldorf Terminated No outcome recorded
Phase 4 NCT00603824 Comparator Jan 2008 → Jul 2009 heparin-induced thrombocytopenia Methodist Healthcare - Memphis Withdrawn No outcome recorded

Evidence & citations 11 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as lepirudin ClinicalTrials.gov intervention name — accepted as the source's own label NCT00003726
3

NCT00603824

NCT00039767

NCT00798525

Known as Hirudin lepirudin ChEMBL registry synonym — accepted as the source's own label CHEMBL1201666
Known as Lepirudin recombinant ChEMBL registry synonym — accepted as the source's own label CHEMBL1201666
Known as Lepirudina ChEMBL registry synonym — accepted as the source's own label CHEMBL1201666
Known as Lepirudine ChEMBL registry synonym — accepted as the source's own label CHEMBL1201666
Known as Recombinant Desulfato Hirudin “A Phase I/II Study of Recombinant Desulfato Hirudin, Lepirudin (Refludan) in Small Cell Lung Cancer Patients Previously Treated With Chemotherapy” NCT00003726
Known as Refludan “A Phase I/II Study of Recombinant Desulfato Hirudin, Lepirudin (Refludan) in Small Cell Lung Cancer Patients Previously Treated With Chemotherapy” NCT00003726
1

“Patients treated with Lepirudin (Refludan®), a direct thrombin inhibitor” NCT00798525

Action Inhibit “lepirudin should be more effective in preventing accumulation of fibrin at the catheter tip because it can counteract the potent clotting enzyme thrombin that is bound in the fibrin” NCT00039767
1

“Thrombin inhibitor” CHEMBL1201666

Modality Protein / enzyme biologic “Recombinant Desulfato Hirudin” NCT00003726
Route Subcutaneous “Patients receive dose escalated lepirudin subcutaneously” NCT00003726
Target F2 “Thrombin inhibitor” CHEMBL1201666